Reprint
Cancer Biomarkers in Body Fluids
Edited by
March 2023
490 pages
- ISBN978-3-0365-6649-8 (Hardback)
- ISBN978-3-0365-6648-1 (PDF)
This book is a reprint of the Special Issue Cancer Biomarkers in Body Fluids that was published in
Biology & Life Sciences
Medicine & Pharmacology
Summary
Liquid biopsy shows promise for cancer screening and diagnostics. This reprint collects recent scientific literature on the identification and application of tumor biomarkers in biological fluids to improve the diagnosis of cancer and the identification of optimal therapeutic strategies.
Format
- Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
primary breast cancer; circulating nucleosomes; circulating tumor cells; plasminogen activator inhibitor-1; cytokines; prostate cancer; breast cancer; circulating tumor cells; treatment decisions; exosomes; molecular composition; cancer pathogenesis; diagnostics; therapeutics; leptomeningeal metastasis; cerebrospinal fluid; extracellular vesicle; biomarker; RNA sequencing; small non-coding RNA; microRNA; exosomes; prostate cancer; exo-oncomiRNAS; TWEAK; semen; rheumatoid factor; autoimmunity; autoantibodies; cancer; biomarker; predictive biomarker; prognostic biomarker; cancer progression; cancer development; immunotherapy; cancer susceptibility; tumor recurrence; tumor load; fecal immunochemical test (FIT); colonoscopy; flexible sigmoidoscopy; liquid biopsy; mRNA; microRNA; ctDNA; proteins; extracellular vesicles; biomarkers; exosome; extracellular vesicles; lung cancer; miRNA; plasma; serum; volatile organic compounds (VOCs); gas chromatography (GC); mass spectrometry (MS); headspace solid phase microextraction (HS-SPME); breast cancer biomarkers; principal component analysis (PCA); linear discriminant analysis (LDA); principal component regression (PCR); liquid biopsy; cfDNA; hereditary and familial pancreatic cancer; somatic mutation profiling; potentially druggable genes; uveal melanoma; circulating tumor DNA; next generation sequencing; PKC inhibitor; liquid biopsy; treatment; response; melanoma; ovarian cancer; lipidomics; lipid; prognosis; ceramide; phospholipid; plasmalogen; biomarker; patient stratification; outcome; personalized medicine; neuroblastoma; immune monitoring; anti-GD2; IL-2; GM-CSF; ASCT; immunotherapy; dinutuximab; exosomes; cancer; liquid biopsy; biomarkers; immunotherapy; anti-PD-1; melanoma; urothelial cancer; immune monitoring; blood biomarkers; NETs; disease modelling; machine learning; metabolic signaling; molecular pathways; plasma metabolites; diagnostic biomarkers; liquid biopsy; urine; urine liquid biopsy; DNA; mRNA; microRNA; sncRNA; bladder cancer; metabolic pathways; metabolism; metabolomics; epigenetics; biomarkers; miRNAs; epigenetic biomarkers; cancer; DNA methylation; micro-RNAs; human papillomavirus; oropharyngeal squamous cell carcinoma; treatment de-escalation; patient stratification; E7 oncoprotein; HPV DNA; HPV antibodies; ELISA; cancer biomarkers; prostate cancer; liquid biopsy; prognosis; diagnosis; early detection; n/a; lung cancer; early diagnosis; biomarkers; liquid biopsy; circulating tumor cells; lung cancer; early diagnosis; cancer biomarkers